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home residents 65 years or older from four states. New typical and atypical users in
nursing homes were followed for up to six month after the exposure without cen-
soring. The risk of death wasmodeled using Cox proportional model and extended
Cox hazardmodel stratified onmatched pairs based on propensity score.RESULTS:
The unadjusted mortality rate was 19.22% for atypical antipsychotic users and
24.27 % for typical antipsychotic users. Cox proportional hazard model revealed
significant increased risk of death [Hazard Ratio (HR) 1.35, 95%; Confidence Interval
(CI) 1.30- 1.63] among typical users when compared to atypical users. The extended
Coxmodel, used due to the violation of proportional hazards assumption, revealed
that risk of death is twice greater among typical antipsychotic users during the
initial 40 days after the start of antipsychotic treatment [HR 2.06, 95%; CI 1.82-2.32]
when compared to atypical users. However, no significant differences were found
after 40 days of antipsychotic exposure. CONCLUSIONS: The use of typical antipsy-
chotic agents was associated with increased risk of death among aged dual eligible
beneficiaries when compared to atypical use, especially within 40 days of treat-
ment, possibly due to their underlying health status.
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Wu CH, Farley J
University of North Carolina, Chapel Hill, NC, USA
OBJECTIVES: The objectives are to estimate the prevalence of comorbid anxiety
and to compare the influence of comorbid anxiety on medication adherence and
health resource utilization among privately insured individualswithMajor Depres-
sive Disorder (MDD).METHODS: Patients withMDD between 18 and 64 years of age
newly initiating an antidepressant between July 1, 2005, and December 31, 2006,
were identified from the MarketScan Commercial Claims database. MDD patients
were defined as having comorbid anxiety if theywere concurrently diagnosedwith
generalized anxiety disorder (GAD), panic disorder (PD), or social anxiety disorder
(SAD).We used a retrospective cohort study design to compare the effect of comor-
bid anxiety disorder on antidepressant adherence measured as proportion of days
covered (PDC), adherence (PDC 80% ), and presence of emergency room (ER) visit
or inpatient encounters. Student t-testswere used to compare adherence rates and
logistic regressions were used to compare health service utilization (ER visit and
hospitalization) between patients with and without comorbid anxiety disorder.
RESULTS: Of 71,467 adults with MDD, 8.4% had GAD, 7.1% had PD, and 6.1% had
SAD. The mean value of PDC among the study population was 0.56. MDD patients
with comorbid anxiety had significantly higher PDC value than patients without
comorbid anxiety (0.58 vs. 0.56, p0.01). MDD patients with comorbid anxiety were
more likely to havemental health-related ER visits than patientswithout comorbid
anxiety after adjusting for age, gender, Charlson comorbidity index, and covariates
associated with prior health care utilization (OR1.16, 95%CI1.10-1.22). However,
there was no difference between patients with and without comorbid anxiety in
the probability of hospitalization. CONCLUSIONS: MDD patients with comorbid
anxiety had higher mental health-related ER visits. Clinicians treating patients
with MDD should consider the role of comorbid anxiety on medication adherence
and clinical outcomes.
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OBJECTIVES: To evaluate performances of various risk adjustment scales in pre-
dicting risk of hospitalization in patients diagnosed with dementia. METHODS:
This cross-sectional study was conducted using the household and medical pro-
vider component files of Medical Expenditure Panel Survey (MEPS) data from 2000
to 2003 (panel 5, 6, and 7). Dementia patients were identified using cccodex and
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-
9CM) codes, and all cause hospitalizations were recorded from the inpatient files.
The risk adjustment scales evaluated in this study were- diagnosis based scales
(identified using ICD-9CM codes): D’Hoore’s adaptation of Charlson comorbidity
index (CCI), and Elixhauser comorbidity algorithm; and prescription based scales
(identified using national drug codes): chronic disease scores (CDS-1 and CDS-2).
Logistic regression models were constructed with all-cause hospitalization as bi-
nary outcome, adjusting for demographic, socio-economic (insurance, income,
geographic region), and perceived health status covariates, and risk adjustment
algorithms. Performance of themodels in predicting hospitalizationwasmeasured
by c-index. RESULTS: Total 392 dementia patients were identified from the house-
hold component files during the study period. Most of the patients were male
(68.58%), white (54.11%), elderly (mean age 73 years), and from a low income family
(59.85%); and almost half of them had an inpatient visit (46.70%). Baseline logistic
model with the covariates only predicted hospitalization risk reasonably well (c
0.602). Performance of risk adjustment models after adjusting for covariates were
as follows- D’Hoore: c 0.688, Elixhauser: c 0.691, CDS-1: c 0.666, CDS-2: c
0.733, CDS-1D’Hoore: c 0.687, CDS-1Elixhauser: c 0.709, CDS-2D’Hoore: c
0.752, and CDS-2Elixhauser: c 0.757. CONCLUSIONS: Diagnosis based scales
performed better than CDS-1 scale in predicting hospitalization. CDS-2 which is a
comorbidity algorithm modified from CDS-1 to efficiently model healthcare utili-
zation and cost performed superiorly. Among the combinations of diagnosis and
prescription based scales CDS-2Elixhauser predicted hospitalization risk most
efficiently.
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OBJECTIVES: Automated tests can assess aspects of cognitive function which can-
not be assessed using traditional non-automated techniques. To build on previous
findings that patients with minimal cognitive impairment show slower informa-
tion retrieval (Nicholl et al, 1995), the present analysis compared 74 patients with
amnestic Mild Cognitive Impairment (MCI) to healthy controls (n1409), and pa-
tients with mild, moderate and moderately-severe Alzheimer’s disease (AD;
n764). METHODS: Three CDR System tests of attention were administered (digit
vigilance, simple and choice reaction time) and two episodic memory tests (word
and picture recognition). For attentionPower of Attention (the ability to focus at-
tention) andContinuity of Attention (the ability to sustain attention)were used. For
recognition, the abilities to correctly identify previous stimuli and reject novel
stimuli were analysed, as was speed of response. RESULTS: For Power of Attention,
and Word and Picture Recognition Speed, there was a clear continuum of decline
from normals through AD. For Continuity of Attention, Word Recognition Accu-
racy, and the ability to recognise previous pictures, MCI subjects demonstrated
preserved functioning equivalent to controls. For the ability to reject novel pic-
tures, MCI patients showed deficits comparable to moderate AD patients. The abil-
ity to reject novel pictures is related to activity in the cingulate gyrus, and the
impairment in MCI suggests disruptions to this area, which may have conse-
quences for neurogenesis. Overall, the pattern of decline is not consistent across all
cognitive functions assessed. CONCLUSIONS: These findings will be discussed in
terms of the likelihood that amnestic MCI is a prodrome of AD, whichmay be the
case for episodic memory as assessed by delayed word recall, but not necessar-
ily for aspects of episodic recognitionmemory or the ability to sustain attention.
This may have implications for treatment of early disease, as well as prevention
strategies.
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Risperidone long-acting injectable (R-LAI) was the first of the ‘atypical’ antipsy-
chotic drugs with delayed release to be marketed worldwide for the treatment of
schizophrenia. This strategy was envisaged to deliver a primary advantage over
conventional oral drugs but could not be demonstrated ahead of marketing ap-
proval as R-LAI was mainly assessed against placebo for that purpose. A risk-
sharing agreement was reached between the manufacturer and the French
National Health Pricing Authority – The Economic Committee on Health Care Prod-
ucts (CEPS), under which coverage would be ensured following demonstration of
cost minimization in real terms. OBJECTIVES: To assess whether R-LAI use was
associated with a decreased risk of hospitalization and provide data for risk-shar-
ing agreement and coverage.METHODS:A cohortwith a ‘dynamic exposure’meth-
odology was used to assess the relative effectiveness of R-LAI. A cohort of adult
patients with schizophrenia was recruited from 177 psychiatric hospitals across
France and observed naturalistically over 12 months. A 3-month granularity was
used for treatment characterization. The relative rate of hospitalization was as-
sessed using a Poisson multiple regression model for auto-correlated data (SAS-
GENMOD). Results were adjustedwith propensity scores using potential confound-
ers of R-LAI use vs. non-use, including history of hospitalization, severity of
schizophrenia, and patterns of antipsychotic use. RESULTS: The cohort consisted
of 1859 patients with 454 person years of R-LAI use, and 1306 person years of R-LAI
non-use. R-LAI use was associated with an adjusted rate ratio of hospitalization of
0.66 (95% CI: 0.460.96) when compared to non-use and 0.53 (95% CI: 0.320.88)
when compared to typical LAI antipsychotics. This was found to be associatedwith
better compliance in patientswith a history of recurrent hospitalization, and there-
fore compensated for the costs of treatment. CONCLUSIONS: A cohort with dy-
namic-exposure methodology established a successful risk-sharing agreement for
a new treatment for schizophrenia.
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OBJECTIVES: The objective of this study is to assess the clinical effectiveness of
naltrexone versus acamprosate and placebo in alcohol dependent patients receiv-
ing psychotherapy. METHODS: Analysis was conducted in accordance with the
principles of systematic review, based on the Cochrane Collaboration guidelines
and the guidelines of the Polish Agency for Health Technology Assessment. Calcu-
lations were performed using the StatsDirect® 2.6.8 statistical package. The ex-
tended evaluation of safety based on sources other than RCTs was performed.
RESULTS: In the light of the analysis carried out it can be concluded that adminis-
tered orally plus psychotherapy for alcohol-dependent patients results in a higher
clinical effectiveness and comparable safety profile in comparison with acampro-
sate for a 1-year-long-observation treatment and placebo for both a short (12-16
weeks) and medium-term observation treatment. Statistical significances in favor
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